Pasar al contenido principal

ESTUDIO DE NUEVAS DIANAS PARA EL TRATAMIENTO DEL SINDROME DE AICARDI-GOUTIERES

PID2022-140603NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models

  • Camarillo, Rosa
  • Prados-Carvajal, Rosario
  • Cruz-García, Andrés
  • Rodríguez-Real, Guillermo
  • Herencia-Ropero, Andrea
  • Serra, Violeta
  • Jimeno, Sonia
  • Huertas Sánchez, Pablo
DNA end resection is a critical step that governs how a broken chromosome will be repaired. As such, it is heavily regulated by multiple cellular signals and processes. Alterations in the regulation of DNA end resection have consequences for cell survival upon exposure to cytotoxic agents, including those used during cancer chemotherapy. Here, we identified several small molecules that affect the process of DNA end resection. Among them, we focus on determining the mode of action of merbarone, a DNA topoisomerase II inhibitor. We uncover a role of the topoisomerase IIβ isoform in the full processing of DNA breaks. Moreover, we show that the effect of merbarone is affected by the formation of G4 quadruplexes and that BRCA1-deficient cancer cells are sensitive to merbarone. Strikingly, this sensitivity can be partially suppressed in cell lines expressing hypomorphic versions of BRCA1 lacking exon 11, a hypomorph that has been linked to PARPi-resistance. Using cellular models, we show that PARPi- and merbarone-resistant BRCA1 exon 11 mutant cells, but not wildtype BRCA1 cells, are sensitive to the combination of both drugs. Finally, we show that combination of merbarone and the PARPi olaparib has a mild antitumor effect in a PARPi-resistant PDX model bearing a BRCA1 exon 11 mutation., This work was funded by the R+D+I grants SAF2013-43255-P, SAF2016-74855-P, PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE to P.H., and grants PID2022-140603NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE and the Ideas Semilla Project IDEAS222767JIME from the Asociación Española Contra el Cáncer (AECC) to S.J and the SINERGIA project SNRGS247052PRAD from AECC to RP-C. RC-D was funded with an FPI fellowship from the Spanish Ministry of Economy and Competitivity. RP-C was funded with an FPU fellowship from the Spanish Ministry of Education and a Postdoctoral Fellowship from the Asociación Española Contra el Cáncer (AECC). AC-G was supported by the Government of Mexico with a fellowship of the CONACYT. CABIMER is supported by the Regional Government of Andalucía (Junta de Andalucía). V.S. received funds from the Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (PI20/00892 and CPII19/00033). AH-R received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). P. Huertas and R. Prados-Carvajal disclose non-financial support from AstraZeneca. Additionally, V. Serra reports research grants from AstraZeneca and personal fees and/or nonfinancial support from AstraZeneca and GSK., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circadian regulation of homologous recombination by cryptochrome1-mediated dampening of DNA end resection

  • Romero-Franco, Amador
  • Checa-Rodríguez, Cintia
  • Jimeno, Sonia
  • Castellano-Pozo, Maikel
  • Aguilera, Paula
  • Miras, Héctor
  • Wals-Zurita, Amadeo
  • Jimeno-González, Silvia
  • López-Contreras, Andrés J.
  • Huertas, Pablo
[Data availability] All relevant data are included in the manuscript.Source data are provided with this paper. ChIP-seq data are deposited at GEO under the accession number GSE261427. All data is available from the authors upon request. Source data are provided with this paper., Genomic stability maintenance requires the repair of DNA breaks in the most accurate fashion. So, an exquisite regulatory network controls the choice between different repair mechanisms to maximize genome integrity. This relies mostly at the level of DNA end resection, the initial steps of the homologous recombination. On the other hand, numerous cellular activities follow a 24 h oscillation known as the circadian cycle. Thus, we explored the regulation of the choice between different DNA break repair pathways along the circadian cycle. Here we show that in human cells DNA resection shows a circadian oscillation, with a peak at early morning followed by a partial and progressive reduction until late afternoon. Such regulation depends on the circadian clock core component CRY1, which modulates the anti-resection activity of CCAR2 to limit CtIP at nightfall. Additionally, such regulation requires DNA-PK-mediated phosphorylation of CRY1. Finally, this circadian regulation impacts cancer progression and response to radiation therapy of specific tumours., This work was funded by the R + D + I grants PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE, the grant P18-RT-1204 from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía and the grant PRYGN246626HUER from the Asociación Española Contra el Cáncer. The mouse work in the ALC laboratory was funded by the R+D+I grant PID2020-119329RB-I00, the SJ lab is funded by the grant PID2022-140603NB-I00, and the SJG lab is funded by the grant PID2022-139253N, all three funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE. MC-P is the recipient of an MSCA-IF-2020 (coDNAres) that covers his salary and part of the reagents. AR-F is funded with a FPU fellowship from the Spanish Ministry of Education and PA was supported by a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313486), and by a postdoctoral grant from the Scientific Foundation of the Spanish Association Against Cancer (POSTD234422AGUI). CABIMER is supported by the regional government of Andalucía (Junta de Andalucía). We thank José Carlos Reyes-Rosa for the critical reading of the manuscript. We also want to thank the Microscopy and Genomic Unit of CABIMER for their support in the experiments., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Radiobiology studies of gold nanoparticle-enhanced radiosensitization in proton therapy

  • Fuster-Martínez, Nuria
  • Saucedo-Cuberes, D. H.
  • Jiménez-Ramos, M. C.
  • Esperante Pereira, Daniel
  • Espino, J. M.
  • Fuster, Juan
  • Belén-Aguilar, J. F.
  • González-López, L.
  • Huertas Sánchez, Pablo
  • Jimeno, Sonia
  • Mingarro, I.
  • Pascual, David
  • Suárez-García, D.
  • García-Murria, M. J.
[Background] Approximately 50 % of newly diagnosed cancer patients worldwide receive radiotherapy, most commonly with X-rays. Proton therapy has emerged as a promising alternative, offering complementary advantages over conventional X-rays due to its highly localized energy deposition at the Bragg peak, thereby reducing radiation exposure to surrounding healthy tissues. In recent years, advances in both technology and biomedicine have driven significant progress in proton therapy, with ongoing research aiming to minimize toxicity and long-term side effects while improving patients' quality of life. An emerging research direction investigates the combination of proton therapy with irradiated nanoparticles acting as radiosensitizers. This approach seeks synergistic effects that could further improve therapeutic outcomes. These effects arise from a complex interplay of physical, chemical, and biological mechanisms. Although previous in vitro and in vivo studies report promising radiosensitization effects of nanoparticles, the literature also includes contradictory results, and the underlying mechanisms remain under debate. This highlighting the need for systematic studies under well-controlled irradiation conditions of different nanoparticles and beam parameters, which are often difficult to perform due to the limited availability of particle accelerators and facilities suitably adapted for such experiments., [Purpose] This work investigates the radiosensitizing effect of gold nanoparticles under proton irradiation and optimizes the irradiation setup to enable more efficient and reproducible future experiments., [Methods] HeLa cells were used as the biological model for the radiobiological experiments. Irradiation conditions were optimized by incorporating a Mylar film into the culture plates to maintain a minimal medium volume and ensure rapid post-irradiation coverage. Cells with and without AuNPs were irradiated with 12.6 MeV proton beams. Radiosensitivity was assessed using clonogenic survival assays, and the radiosensitizing effect, together with its associated uncertainty, was quantified. DNA damage analysis was also performed to corroborate the observed effects and explore underlying mechanisms., [Results] The radiobiology experiments confirmed and quantified a significant radiosensitizing effect of gold nanoparticles (AuNPs) on HeLa cells at doses from 4 Gy, with Sensitization Enhancement Ratio (SER) values of 1.53 ± 0.07 in 2022 and 1.30 ± 0.20 in 2023 using 50 nm diameter AuNPs. Experiments in 2023 with 20 nm diameter AuNPs yielded a comparable SER of 1.38 ± 0.18, indicating no significant size-dependent differences. The radiosensitizing effect exhibited dose-dependent amplification, with higher doses producing greater cell killing. Linear-Quadratic (LQ) model fits showed an increased 𝛼 parameter in the presence of AuNPs, consistent with an increase in non-repairable damage. This trend was further supported by double-strand break assays. Furthermore, oxidative stress assays showed that AuNPs do not increase basal ROS levels, but enhance ROS production under oxidative stress conditions., [Conclusion] The radiobiology experiments presented quantitatively confirm that both 20 and 50 nm diameter AuNPs enhance the radiosensitivity of HeLa cells under proton irradiation. The radiosensitizing effect increases with dose, indicating a dose-dependent response, while no significant differences were observed between nanoparticle sizes. Consistent trends of increased DNA double-strand breaks further support the observed radiosensitization. Evidence from oxidative stress assays suggests that AuNPs may enhance ROS production under oxidative conditions, potentially contributing to the observed radiosensitization and DNA damage., This work was supported by the Generalitat Valenciana through the grant CDEIGENT2021/012 and CIPROM/2022/062. Also by the Spanish Ministry of Science and Innovation (MCIN/AEI/FEDER/UE) through grants PID2021-123879OB-C21, PID2022-140603NB-100 and PID2023-152568NB-100, funded by MCIN/AEI/10.13039/501100011033/ and by “ERDF A way of making Europe” as well as by the Ideas Semilla Project IDEAS222767JIME from the Spanish Association Against Cancer (AECC). Furthermore, financial support was provided by the European Union–NextGenerationEU and the Regional Ministry of University, Research and Innovation of the Junta de Andalucía through the Recovery, Transformation and Resilience Plan (PRTR) and the Complementary Plan in Astrophysics (subproject C17.I01.P01.S17, public grant ASTRO21/1.4/4)., Peer reviewed